July 28 marks World Hepatitis Day—a timely reminder that liver health transcends body weight. While nonalcoholic fatty liver disease (NAFLD) is often associated with obesity, a growing number of individuals with normal or low body mass index (BMI) are receiving ultrasound diagnoses of hepatic steatosis. This “lean NAFLD” phenotype—defined as NAFLD in individuals with BMI <23 kg/m² in Asian populations or <25 kg/m² in Western cohorts—is not merely an anomaly; it represents a distinct clinical entity with unique pathophysiology, heightened risk for fibrosis progression, and frequent diagnostic delay.
Unlike obesity-related NAFLD, lean NAFLD is less driven by caloric surplus and more closely tied to underlying metabolic dysfunction—even in the absence of overt adiposity. Four key mechanisms explain why fat accumulates in the livers of slender individuals:
1. Visceral adiposity masquerading as leanness. Some individuals exhibit normal BMI but elevated waist circumference (>90 cm in Asian men, >85 cm in Asian women; >102 cm in Western men, >88 cm in Western women), signaling excess intra-abdominal fat. This metabolically active visceral adipose tissue releases free fatty acids directly into the portal circulation, overwhelming hepatocyte oxidative capacity and promoting de novo lipogenesis.
2. Skeletal muscle insufficiency. Low muscle mass—often resulting from sedentary behavior or inadequate protein intake—reduces whole-body insulin sensitivity and impairs glucose disposal. As a consequence, excess circulating glucose and lipids are shunted toward the liver for storage, accelerating hepatic triglyceride accumulation independent of total body fat.
3. Dietary drivers beyond dietary fat. High intake of refined carbohydrates—including white rice, noodles, sugary beverages, and fructose-rich foods—triggers hyperinsulinemia and upregulates sterol regulatory element-binding protein-1c (SREBP-1c), a master transcriptional regulator of lipogenic enzymes. Fructose, in particular, undergoes first-pass hepatic metabolism without hormonal regulation, rapidly converting to acetyl-CoA and fueling triglyceride synthesis.
4. Genetic predisposition. Polymorphisms in genes such as PNPLA3 (rs738409), TM6SF2 (rs58542926), and MBOAT7 are strongly associated with increased hepatic fat content and fibrosis risk—even among lean individuals. A family history of type 2 diabetes, dyslipidemia, hypertension, or NAFLD significantly elevates susceptibility, underscoring the importance of genetic background over anthropometric metrics alone.
Clinically, lean NAFLD carries a paradoxical prognosis: although these patients often present later due to lower clinical suspicion, they demonstrate higher rates of advanced fibrosis at diagnosis compared with their overweight counterparts. Five high-risk subgroups warrant targeted screening and early intervention:
1. Individuals with recent, rapid, or extreme weight loss—particularly those who adopted very-low-calorie, low-protein, or carbohydrate-restricted diets. Protein deficiency compromises synthesis of apolipoprotein B-100, impairing very-low-density lipoprotein (VLDL) assembly and export of triglycerides from hepatocytes. This leads to intracellular lipid retention despite weight reduction—manifesting as fatigue, jaundice, or hypoalbuminemia.
2. Those with central adiposity and normal BMI—common among office workers with prolonged sitting and frequent social drinking. Elevated visceral fat drives chronic low-grade inflammation and systemic insulin resistance, creating a permissive environment for hepatic steatosis and stellate cell activation.
3. Adults with low muscle mass and high body fat percentage (“sarcopenic obesity” phenotype). These individuals exhibit reduced basal metabolic rate and diminished capacity for fatty acid oxidation. Their lean appearance belies compromised metabolic resilience, making reversal more challenging and relapse more likely.
4. Habitual consumers of sugar-sweetened beverages and ultra-processed carbohydrates, especially when combined with circadian disruption (e.g., chronic sleep deprivation or shift work). Nighttime sleep is critical for hepatic autophagy and lipid turnover; its disruption suppresses AMPK signaling and amplifies lipogenesis.
5. Patients with a first-degree family history of metabolic disease. Genetic risk interacts synergistically with shared environmental exposures—making annual surveillance essential regardless of BMI.
Management must be phenotype-specific—not one-size-fits-all:
For those recovering from restrictive dieting: Prioritize protein repletion (1.2–1.6 g/kg/day from diverse sources including fish, eggs, legumes, and dairy), replace refined grains with intact whole grains and pulses, and initiate low-intensity aerobic activity followed by progressive resistance training to restore lean mass and VLDL export capacity.
For individuals with elevated waist circumference: Eliminate added sugars and ultra-processed foods; emphasize fiber-rich vegetables and monounsaturated fats; combine moderate-intensity aerobic exercise (≥150 min/week) with core-strengthening resistance training to preferentially reduce visceral adipose tissue.
For those with sarcopenia: Implement structured resistance training (2–3 sessions/week targeting major muscle groups) alongside consistent protein distribution across meals. Muscle hypertrophy improves insulin-mediated glucose uptake and reduces hepatic gluconeogenic demand.
For patients with circadian and dietary dysregulation: Prioritize sleep hygiene (7–9 hours/night, consistent bedtime/wake time) before initiating aggressive dietary modification. Only then should fructose and refined carbohydrate intake be systematically reduced—replacing them with low-glycemic-index whole foods and increasing cruciferous vegetable consumption to support phase II detoxification pathways.
For genetically susceptible individuals: Adhere rigorously to lifestyle guidelines while undergoing annual monitoring—including liver ultrasound, serum ALT/AST, fasting glucose, HbA1c, lipid panel, and, where indicated, transient elastography or MRI-PDFF for fibrosis staging. Early pharmacologic intervention may be warranted if metabolic comorbidities emerge.
Early detection remains paramount: Lean NAFLD is typically asymptomatic. Clinicians and patients alike must move beyond BMI-centric thinking. Waist circumference measurement—taken at the midpoint between the lower rib margin and the iliac crest—should be routine. Persistent fatigue, right upper quadrant discomfort, morning bitterness, or unexplained elevation in ALT warrants prompt hepatic evaluation. Abdominal ultrasound and comprehensive liver biochemistry provide accessible, cost-effective assessment—and together offer a reliable window into both hepatic structure and systemic metabolic health.
Body weight is neither a shield nor a sentence for liver disease. Vigilant screening, precise phenotyping, and personalized intervention—not assumptions about leanness—are what safeguard hepatic integrity. With timely action, even established lean NAFLD can regress, underscoring that metabolic health is modifiable at any size.